Drugs / adenovirus-mediated human interleukin-12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00849459 | Aug 2008 → Jun 2011 | breast cancer | Max Sung | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | adenovirus-mediated human interleukin-12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00849459 ↗ |
| Route | Other | “Patients receive a single dose of adenovirus-mediated human interleukin-12 intratumorally via percutaneous needle placement under ultrasound guidance.” NCT00849459 ↗ |